The Effect of Outpatient Ketamine Infusion on Chronic Neuropathic Pain and PTSD

This prospective randomised trial (n=30) will evaluate the effects of outpatient ketamine infusion on chronic neuropathic pain and PTSD in a military population.

Participants will be randomised to receive either moderate dose ketamine, moderate dose ketamine with magnesium, or magnesium alone.

The study will assess self-reported pain and PTSD questionnaires over a ~24-week period, aiming to provide evidence for the utility of ketamine in managing neuropathic pain and associated comorbidities among military personnel.

The trial started in May 2024 and is expected to finish in May 2027.

Topic Pain PTSD
Compound Ketamine
Country United States of America
Visit trial
Status Not yet recruiting
Results Published No
Start date 01 May 2024
End date 31 May 2027
Phase Phase IV
Design Blinded
Type Interventional
Generation First
Participants 27
Sex All
Age 18- 70
Therapy No

Trial Details

This study is aimed to evaluate outpatient ketamine infusion within a military chronic neuropathic pain population and its effect on PTSD. Currently, this is a pilot study with 30 participants. Participants will be randomized to (1) a moderate dose ketamine, (2) moderate dose ketamine +Mg, or (3) a magnesium control group. Participants will complete self-reported pain and PTSD questionnaires throughout the ~24-week study period. The outlined strategy will provide evidence for the utility of ketamine in neuropathic pain management and pain associated comorbidities within a military population.

Trial Number NCT06414356

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.